Paul Fehlner: How pharma companies use patent rights to limit their tax exposure

In an investigation published by Noteworthy, Investigate Europe reveals how pharma firms maximise profits in Ireland as patients struggle with drug prices.
Here, Paul Fehlner, former head of IP at Novartis, a Swiss pharma behemoth, explains how "everyone who has income wants to limit the tax exposure that they have from that income, companies are no exception".
He answers the questions:
- How do pharma companies lower their taxes?
- Why do companies try to prolong their patents?
Read the full investigation: www.noteworthy.ie/investigate-...
Investigate Europe (www.investigate-europe.eu) is a non-profit journalistic cooperative with members from 11 countries. Noteworthy is the crowdfunded investigative journalism platform from The Journal, and is the Irish publication partner for this series.
For more on Noteworthy see www.noteworthy.ie/
► Twitter: / noteworthy_ie
► Facebook: / noteworthy.ie
► Instagram: / noteworthy.ie